Building National Patient Registries in Mexico: Insights from the MexOMICS Consortium.

Paula Reyes-Perez¹⁺, Ana Laura Hernández-Ledesma¹⁺, Talía V. Román-López²⁺, Brisa García-Vilchis³, Diego Ramírez-González², Alejandra Lázaro-Figueroa³, Domindo Martínez^{1,4,5}, Victor Flores-Ocampo¹, Ian M. Espinosa-Méndez², Miguel E. Rentería^{6,7}, Alejandra E. Ruíz-Contreras³, Sarael Alcauter², Alejandra Medina-Rivera¹.

- 1. Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Blvd. Juriquilla 3001, 76230, Santiago de Querétaro, México.
- 2. Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Campus Juriguilla, Blvd. Juriquilla 3001, 76230, Santiago de Querétaro, México.
- 3. Laboratorio de Neurogenómica Cognitiva, Unidad de Investigación de Psicobiología y Neurociencias, Coordinación de Psicobiología y Neurociencias, Facultad de Psicología, Universidad Nacional Autónoma de México. Av. Universidad 3004, Col. Universidad Nacional Autónoma de México, 04510, CdMx, México.
- 4. Unidad de Genómica Avanzada, Langebio, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Libramiento Norte León Km 9.6, 36821, Irapuato, Guanajuato, México.
- 5. Escuela Nacional de Estudios Superiores, Unidad Juriquilla, Universidad Nacional Autónoma de México, Juriquilla, 76230, Santiago de Querétaro, México.
- 6. Mental Health and Neuroscience Program, QIMR Berghofer Medical Research Institute, 4006, Brisbane, Queensland, Australia.
- 7. School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, 4006, Brisbane, Queensland, Australia.
- + These authors contributed equally.

*Corresponding authors

Sarael Alcauter Instituto de Neurobiología, Universidad Nacional Autónoma de México, Phone: (+52)4422381053; e-mail: alcauter@inb.unam.mx

Alejandra Medina-Rivera Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México Phone: (+52)5556234331; e-mail: amedina@liigh.unam.mx

Alejandra E. Ruiz-Contreras

Facultad de Psicología, Universidad Nacional Autónoma de México, NoTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Phone: (+52)5256222568; e-Mail: <u>aleruiz@unam.mx</u>

ABSTRACT

OBJECTIVE: To introduce MexOMICS, a Mexican Consortium focused on establishing electronic databases to collect, cross-reference, and share health-related and omics data on the Mexican population.

METHODS: The Mexican Twin Registry (TwinsMX), Mexican Lupus Registry (LupusRGMX) and the Mexican Parkinson's Research Network (Mex-PD) were designed and implemented using Research Electronic Data Capture web-based application. Registries were compiled through voluntary participation and on-site engagement with medical specialists. In some instances, DNA samples and Magnetic Resonance Imaging images were also acquired.

RESULTS: Since 2019, the MexOMICS Consortium has successfully established three electronic-based registries: TwinsMX (n=2915), LupusRGMX (n=1761) and Mex-PD (n=750). In addition to sociodemographic, psychosocial, and clinical data, MexOMICS has collected samples for genetic determinations across the three registries. Cognitive function assessments, conducted using the Montreal Cognitive Assessment, have been administered to a subsample of 376 Mex-PD participants. Furthermore, a subset of 267 twins underwent measurements of structural, functional, and spectroscopy brain images; comparable evaluations are projected for LupusRGMX and Mex-PD.

CONCLUSIONS: The MexOMICS registries offer a valuable repository of information concerning the potential interplay of genetic and environmental factors in health conditions among the Mexican population.

Keywords:

Patient registries, genetics, twins, systemic lupus erythematosus, parkinson disease.

INTRODUCTION

Brief history of patient registries

Patient registries are organized systems that collect, store and analyze information about individuals living with a particular health condition¹. They are used for clinical research, recruitment into clinical trials, and improving patient care². When coupled with genomic information, they provide further opportunities for genomic medicine and research³.

The National Leprosy Registry of Norway, established in 1856, was presumably the first national patient registry, implemented as a response of the high prevalence of leprosy at the time, and included a collaborative effort between health officers and ministers of the church, which resulted in the policy of isolation that ultimately led to the disappearance of leprosy in Norwav⁴.

Since then, several registries have been set around the globe with various aims. As expected, the two leading causes of death, cancer and heart diseases, have led the efforts through the past century. Nowadays, there are at least 343 cancer registries in 65 countries⁵, while 155 Cardiac disease registries in 49 countries have enrolled 73.10 million patients⁶. One of the greatest examples of this is the US National Cardiovascular Data Registry (NCDR), which comprises 10 registries and has more than 60 million records now entering the qualification of Big Data⁷. In Latin America, population-based cancer registries, which arguably are the most extensively documented among patient registries, cover 20% of the population, and only 7% of these are considered to contain high-quality information⁸.

Although usually patient registries aim to estimate the prevalence of a disease or trait within a population, and establish what demographics and environmental factors affect risk, they don't always aim to estimate how much a trait is explained by genetic or environmental factors. Historically, twins' registries have been frequently used to improve our comprehension of human health and the genetic and environmental basis of complex diseases⁹. The classical twin design consists of acquiring phenotypic data of monozygotic (MZ) and dizygotic (DZ) twins and measuring how correlated a trait is within pairs of both types. The heritability of a trait, the percentage of variance explained by genetic factors, can be estimated through the difference between the correlation of MZ twins and DZ twins. The rest of the variance in that trait could be explained by environmental factors. Other research designs might also acquire data from other family members of the twin participants, the so-called extended twin design, or acquire data of MZ twins adopted to different households. However, twin studies are not just limited to estimating the heritability of a trait, they can also estimate how two different traits have genetic and environmental factors in common explaining their variance. They can also aid in establishing causal relationships between two associated traits, for example, MZ twins discordant in cannabis consumption could help to determine whether cannabis does cause lower cognitive functioning or not. Thus, the information generated through twin registries has allowed us to deepen the genotype-environment interactions, how they shape the mechanisms that lead us to

our individual differences and the influence of these mechanisms in health and disease conditions⁹. Furthermore, Latin America has allegedly the smallest sample size for twin registries, of around 5000 individuals, Brazil being the country with most registries (n=4826), followed by Mexico⁹.

Thus the often mandatory implementation of patient records and twin registries across some countries has promoted relevant progress¹⁰. Nevertheless, still a considerable fraction of the world's population remains uncovered, particularly in African and Asian countries¹¹, due to the struggle to collect and integrate data to establish and maintain national registries¹².

The context of Mexican health records systems

Although healthcare in Mexico has certainly improved its coverage and scope over the last two decades¹³, according to the 2020 census, about 33 million people in the country remain with no health services insurance¹⁴ and 48.49% have no effective access to health services¹³.

Considering that leading causes of death in Mexico include heart disease, diabetes and malignant tumors¹⁵ initiatives such as the Mexican Registry of Atrial Fibrillation (ReMeFa)¹⁶, the Mexican Registry of Pediatric Cardiac Surgery¹⁷ and the National Registry of Cardiac rehabilitation programs (RENAPREC), have been recently established. But it seems that in some cases efforts must be reinforced; for instance, the National Heart Failure Registry Program¹⁸ was initiated in 2002 with the sole purpose of having a general characterization of patients with this condition, once the aim was achieved in 2004, the project was no longer pursued.

In recent years, valuable efforts have been made to establish registries in Mexico for patients living with conditions such as osteoarthritis¹⁹, diabetes²⁰, atrial fibrillation²¹. Although a federal norm (NOM-024-SSA3-2012, issued in 2012) was established to regulate the Electronic Health Record Information Systems²², the diversity of electronic clinical records and database storage systems greatly hinder data sharing and interaction among health institutions²³. In addition, these registries are mainly survey-based and lack biobanking or genetic analyses, unlike their homologs in the European population, which limits their scope^{24–26}.

The MexOMICS Consortium was created with the aim to design and implement an infrastructure that allows the consolidation of electronic-based databases with the ability to collect, compare, cross-reference, and share valuable information about Mexican people with different healthcare related conditions. The consortium is currently focused on three traits in the admixed Mexican population: a) twins and members of multiple births (*TwinsMX*)²⁷, b) people with Systemic Lupus Erythematosus (*LupusRGMX*)²⁸ and c) patients with Parkinson Disease (*MEX-PD*)²⁹. To our knowledge, there is a lack of other nationwide registries that include genetic data, and publicly available information characterizing Mexican people with these traits in addition to the valuable clinical and sociodemographic information that the

developed databases could provide, these include genetic profiling and biobanking with the aim to expand our knowledge of the influence of genetic-environmental interactions on the phenotypic characteristics of the Mexican population and their potential implications on health and disease. In the present work, we will discuss the design, implementation and operational issues, current state and future directions of these three registries.

METHODS

Ethics and data protection

All three registries were approved by the Ethics on Research Committee of the Institute of Neurobiology at Universidad Nacional Autónoma de México (UNAM). TwinsMX was the first registry, established in 2019; followed by LupusRGMX and MEX-PD in 2021. Information is anonymized and stored at the National Laboratory of Advanced Scientific Visualization at UNAM. Participants provided informed consent prior to registration, and a privacy statement was given to them, in accordance with the Federal Law on the Protection of Personal Data Held by Private Parties.

Platform and surveys design and implementation

Each registry follows specific guidelines in order to obtain necessary data. For such purposes, surveys are available on web-based application Research Electronic Data Capture (REDCap), which allows secure capture and storage of data^{30,31}. Instruments integrated in the three registries are summarized in **Table 1** to provide a general picture of the type of information that is being collected.

In general, all three projects share an initial structure, with questionnaires focused on identifying socio demographic traits, characterizing medical history and mental health. The shared technology information infrastructure of the registries has allowed us to design, implement and validate surveys in one of the registries to further establish it in the other registries. Beside these shared questionnaires, each registry includes surveys focused on bringing light on specific traits associated with the studied population, such as zygosity in TwinsMX or cognitive impairment in MEX-PD.

Although the selection of each instrument responds to particular research questions one major guideline is the ability to produce harmonized measures to link and compare the data across registries and their counterparts in other populations ³². For instance, TwinsMX is built to be comparable to the Australian ³³ and United Kingdom ³⁴ Twins Registries', while MEX-PD is akin to the newly established Australian Parkinson's Genetics Study³⁵ and the Latin American Research Consortium on the Genetics of Parkinson's Disease³⁶.

Table 1. Instruments employed and information required in TwinsMX, LupusRGMX and MEX-PD registries. In bold letters are presented the variables and instruments shared by two or more registries.

| | Description | | | |
|--------------------------------|---|---|---|--|
| Section | TwinsMX | LupusRGMX | MEX-PD Full name Date of birth Age Contact information. Occupation Last educational degree State of residency Ethnicity Ancestry Genealogy | |
| Sociodemograp hic variables | Full name Date of birth Age Contact information. Occupation Last educational degree (participants and parents) State of residency Family's income in minimum wages | Full name Date of birth Age Contact information. Occupation Last educational degree State of residency Number of habitants in home Socioeconomic level index rule of the Mexican Association of Market and Opinion Intelligence Agencies (AMAI) ³⁷ | | |
| Medical history | Personal and family history of cardiovascular, metabolic, endocrine, neoplastic, respiratory, psychiatric, neurologic, urinary, reproductive, gastrointestinal, rheumatologic, developmental, pregnancy, dermatologic, and ophthalmologic disorders, surgical history and medication use | Personal and family history of cardiovascular, metabolic, endocrine, neoplastic, respiratory, psychiatric, neurologic, urinary, reproductive, gastrointestinal, rheumatologic, developmental, pregnancy, dermatologic, and ophthalmologic disorders, surgical history and medication use. Inclusion and exclusion criteria that support lupus diagnosis: Lupus associated symptoms and clinical | Clinical site and neurologist where the participant is registered. Inclusion and exclusion criteria that support PD diagnosis: Motor and non-motor symptoms Medication Specific scales: Unified Parkinson's Disease Rating Scale (MDS- UPDRS) ⁴⁰ and the Hoehn & Yahr scale ⁴¹ | |

| | Use of hormon | al treatments | Not applied |
|--------------------------|---|--|---|
| Reproductive health | Menstruation Pregnancy Breastfeeding | | PD women-specific questionnaire 57 |
| Environmental factors | Parental Bonding Childhood Trauma | | Questionnaires about pesticides, heavy metals and water, air or soil contaminants exposure and head trauma. |
| Cognitive function | Brief IQ test (Shipley- 2) ⁴⁹ , Synchronization- continuation task ⁵⁰ , and Speech-to-Speech Synchronization task ⁵¹ Spatial n-back (0,2-b) task for assessing working memory during fMRI ⁵² Creyos' computerized cognitive battery of 12 tasks ⁵³ | Montreal Cognitive Assessment (MoCA) soon to be applied ⁵⁴ | Montreal Cognitive Assessment (MoCA) ⁵⁴ Creyos' computerized cognitive battery , 8 selected tasks ⁵³ |
| Mental health | State-Trait Depression Inventory (IDERE) ⁴² State-Trait Anxiety Inventory (IDARE) ⁴³ Paranoid ideation Psychoticism and others ⁴⁴ Self-confidence Social competence Family support Ability of people to organize themselves in difficult times ⁴⁵ | State-Trait Depression Inventory (IDERE) ⁴² State-Trait Anxiety Inventory (IDARE) ⁴³ Symptom Checklist, Revised (SCL-90-R) ⁴⁶ Coping Strategies Inventory (CSI) ⁴⁷ Mexican resilience scale (RESI-m) ⁴⁵ | State-Trait Depression Inventory (IDERE) ⁴² State-Trait Anxiety Inventory (IDARE) ⁴³ Symptom Checklist, Revised (SCL-90-R) ⁴⁶ Parkinson Anxiety Scale ⁴⁸ |
| | | manifestations based on Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) ³⁸ and the American College of Rheumatology (ACR) criterias ³⁹ Treatment | |

| Lifestyle and quality of life | Pittsburgh Sleep Quality Index ⁵⁸ World Health Organization Quality of Life (WHOQoL- bref) ⁵⁹ 36-Item Short Form Health Survey (SF- 36) ⁶⁰ | Pittsburgh Sleep Quality Index ⁵⁸ World Health Organization Quality of Life (WHOQoL- bref) ⁵⁹ 36-Item Short Form Health Survey (SF- 36) ⁶⁰ Lupus Quality of Life (LupusQoL) ⁶¹ | | |
|-------------------------------|---|--|---|--|
| Personality traits | Big Five Personality inventory ⁶² Behavioral Activation System and Behavioral Inhibition System ⁶³ | Big Five Personality inventory ⁶² | Not applied. | |
| Diet and eating behaviors | Food intake Food-related behaviors Traits suggestive of eating disorders ⁶⁴ | | Not applied. | |
| Physical activity | Global Physical Activity Questionnaire (GPAQ) ⁶⁵ | | Not applied. | |
| Substance use and abuse | Frequency and amount of: Tobacco ⁶⁶ , Alcohol Use Disorders Identification Test (AUDIT) ⁶⁷ , Cannabis Use Disorders Identification Test (CUDIT) ⁶⁸ , Consumption of other drugs Substance use disorder identification. | Not applied. | Frequency and amount of: Tobacco Alcohol Caffeine | |
| Cognitive reserve | Not applied | | The Cognitive Reserve Index Questionnaire ⁶⁹ | |

| Zygosity | Evaluation of the similitude of phenotypic physical traits and the frequency that their relatives confound twins. This questionnaire identifies if twins are identical (monozygotic) or nonidentical (dizygotic) with an accuracy of 98% ⁷⁰ | Not applied. |
|------------|--|--------------|
| Laterality | Edinburgh Handedness Inventory ⁷¹ | Not applied. |

Project identity

The term *-omics* has been widely used in recent years to address specific fields in biological sciences research, such as the study of the genome (genomics) or the study of the metabolome (*metabolomics*)⁷². MexOMICS reflects our aim to study health related conditions in the Mexican population from a multidisciplinary approach; evaluating not only the clinical data, but also integrating the role of genetic and environmental factors. As for the logo, "MexOMICS" name is accompanied by four entangled DNA strands each representing the conjunction of projects (TwinsMX, LupusRGMX and Mex-PD) in a Mexican styled design that resembles the ollin (movement) prehispanic symbol.

For the Mexican Twin Registry, Registro Mexicano de Gemelos in Spanish, the acronym TwinsMX was selected; "Twins" to highlight the multiple births and "MX" for Mexican. The logo is centered in this acronym and includes "Registro Mexicano de Gemelos" in the bottom part. The "I" and "X" letters include two dots on the top, resembling a pair of heads, representing the pairs of twins (Figure 1B). Color palette includes bright green and a shade of pink known as Mexican pink in our culture; both colors are widely used on traditional artisanal crafts and therefore represent the vibrancy of our culture, as well as the spirit, charisma, liveliness, and vitality of our people. TwinsMX's website (https://twinsmxofficial.unam.mx/) includes the "Sign up" section, along with an "About us" section focused on the academic profiles of the TwinsMX team members, frequently asked questions, information about the projects well as interactive section that allow the people to see how is the registry advancing through time. It also includes a "Blog" section focused on sharing science-based information of interest in a non-technical language. TwinsMX was launched in May 2019 and represents the first platform implemented by our consortium.

For the Mexican Lupus Registry's acronym, the word Lupus was selected as the central element; followed by the letters "RG", from ReGistry and "MX", from MeXican. The registry's logo includes the acronym along with "Registro Mexicano de Lupus" in medRxiv preprint doi: https://doi.org/10.1101/2023.09.11.23295377; this version posted September 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .

the bottom part, and integrates a butterfly, which resembles the malar rash, one of the most common manifestations of SLE, along with a meaning of hope; the purple color palette was selected because of its wide utilization in awareness campaigns as it symbolizes a middle point between the intensity and motivation of the red and the calmness and stability of the blue (Figure 1B). The website (https://lupusrgmx.liigh.unam.mx/) was created considering the same color palette and it includes a "who are we" section which includes academic profiles of the research team members, a "Communication" part with the structure of an informative blog, a "Lives" section that resumes the facebook lives hosted by members of the project, a "Contact" section to provide a communicative platform with the team, and the "Sign up" button to access to the registry. LupusRGMX was successfully launched in May 2021, was socialized through a live session via facebook, and have worked since then using these platforms.



Figure 1. Logos designed for A) MexOMICS, B) TwinsMX, C) LupusRGMX and D) MEX-PD.

The Mexican Parkinson's Research Network, Red Mexicana de Investigación en Parkinson in Spanish, is represented with the acronym "MEX-PD" which includes "MEX" for Mexican and "PD" for Parkinson Disease (Figure 1C). The logo includes a tulip silhouette, a flower that has been broadly used to raise awareness about Parkinson disease since a horticulturist living with PD developed a new variant of tulip and named it after Dr. James Parkinson, the first physician to describe and document the disease. MEX-PD website (<u>https://mexpd.liigh.unam.mx/</u>) includes a "Frequent asked questions" section, an "About us" section that includes the academic information about the team and a "Pre-registry" option. MEX-PD was launched in July 2021.

Volunteers' recruitment

As one of the main objectives of the registries is to include as many Mexicans as possible across the country, it became evident that a decentralized approach was needed. Given the varied nature of each registry, specific procedures for participants recruitment have been followed: for TwinsMX the enrollment is made through social

media campaigns and on-site events invitations. Given the complexity of PD diagnosis the recruitment in MEX-PD requires the clinical expertise of neurologists: a team of neurologists of different sites across México has been assembled and volunteers are being identified and registered through their practice. For LupusRGMX the recruitment relies on a hybrid strategy: A team of rheumatologists is actively registering patients in their practice, and through social media and on site events where volunteers are invited to self-register.

RESULTS

Progress at a glance

As of June 2023, our registries included 2915 volunteers for TwinsMX (April 28th, 2023), 1761 participants for LupusRGMX (June 21st, 2023) and 750 for MEX-PD (June 29th, 2023) (Table 2); additionally, for LupusRGMX 153 participants were registered as controls, whereas MEX-PD has 397 volunteers registered as nonaffected controls. The female participation represents the 71.9% of TwinsMX, the 94.3% in LupusRGMX and the 59.2% in MEX-PD, whereas 28.1%, 6.7% and 40.8% of male participation was respectively observed in each registry.

| Information | TwinsMX (n=2915*) | LupusRGM X (n=1761) | MEX-PD (n=750) |
|--|-----------------------------|------------------------------|----------------------------------|
| Gender (n,%) <i>Female Male</i> | 2096 (71.9%) 819 (28.1%) | 1662 (94.3%) 99 (6.7%) | 444 (59.2%) 306 (40.8%) |
| Age at enrollment (mean,SD) | 29.2±11.2 | 37.1±10.9 | 62.17±10.6 |
| Time with the diagnosis (mean, SD) | NA | 8.5±7.8 | NA |
| Age at diagnosis (mean,SD) | NA | 28.3±10.9 | NA |
| Genetic samples obtained (n,%) | 232 (7.9%)** | 108 (6.1%) | 495 (66%) |
| MRI sampled (n) | 267 (9.1%) | To start in fall 2023 | To start in fall 2023 |
| Cognitive function evaluations | 267 (9.1%)** | To start in fall 2023 | 376 (50.1%) |

| Table 2. Sociodemographic characteristics of volunteers across re | gistries. |
|---|-----------|
|---|-----------|

* Individual subjects

** Subjects in MRI study

Since 2020 TwinsMX includes participation of pediatric volunteers, always with the consent of a parent or legal tutor, this is reflected in the age distribution of the cohort, which covers a range from 0 to 80 y/o, with the majority among 20 and 40 y/o (Figure 2A1), and a mean age of 29.2±11.2 y/o at the moment of enrollment. Distribution among monozygotic and dizygotic participants is shown in Fig XX, and a similar pattern can be observed in both groups.

In the case of LupusRGMX only adults (people over 18 y/o) can participate, age range in the registry is between 18 to 80 y/o(Figure 2B1), with the majority of the cohort between 20 and 45 y/o, with a mean age of diagnosis of 28.3±10.9 y/o. Healthy controls age distribution is also exhibited, with a range from 10 to 60 y/o, and the majority of volunteers being in their early 20s.

For MEX-PD the age of participants ranges from 40 to 90 y/os (Figure 2C1), this is due to the selection criteria that requires a minimum age of 40y/o, with the majority being between 60 and 80 y/o and a mean age of 62.17±10.6 y/o. Control participants exhibited a similar range, but with many of the volunteers among 40 and 60 y/o.

As mentioned, genetic analyses and other clinical measurements can help enrich the information collected through the registries, giving insights into the biological conditions of our participants. In this line, our team has been recovering DNA samples from volunteers of the three projects. To date, 109 samples have been recovered to perform whole genome sequences in LupusRGMX, of which 62 have been successfully sequenced; simultaneously 50 samples have been obtained to perform single cell RNA-seq. In the case of MEX-PD 495 samples have been obtained to perform genotyping. TwinsMX has a total of 232 available samples, of which 94 have already been genotyped, 82 are ready for genotyping, and the rest will be processed and genotyped in the next months.

As the nervous system is highly compromised in Parkinson's disease, cognitive function has also been evaluated by the Montreal Cognitive Assessment (MoCA) to 126 controls and 250 patients. Due to the high prevalence and severity of neurological related manifestations in SLE (also known as neurolupus) LupusRGMX will apply 90 MoCA evaluations by 2024. Additionally, structural, functional and spectroscopy brain images have been acquired through MRI sessions of a subsample of 267 TwinsMX volunteers. MEX-PD and LupusRGMX will perform at least 90 MRI evaluations each by 2024.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.11.23295377; this version posted September 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.






Figure 2. Geographic and age distribution of volunteers for TwinsMX (n=2915), LupusRGMX (n=1761) and E=MEX-PD (n=774). Age distribution for TwinsMX (upper-left), LupusRGMX (middle-left) and MEX-PD (bottom-left). Geographic distribution for TwinsMX (upper-right), LupusRGMX (middle-right) and MEX-PD (bottom-right).

Regarding geographical coverage of the three projects, we have an important participation of volunteers from the center of México, this is probably due to the physical location of the leading laboratories (Mexico City and Queretaro). In TwinsMX (Figure 2A2) the majority of registers are concentrated in México City (n=1176), México (n=295), Veracruz (n=149), Jalisco (n=111), Puebla (n=105), and Guanajuato (n=101), with less participation among people from the north-western and south regions. For LupusRGMX (Figure 2B2) we can observe a higher participation among people living in México City (n=255), México (n=145) and Querétaro (n=119); whereas the west and northern west regions are the less represented. In the case of MEX-PD (Figure 2C2) most of the registries come from México City (n=71), México (n=62),

and Nuevo León (n=42); the states with no volunteers registered are shown in light gray.

Challenges and limitations

The implementation of a National Registry always faces challenges, especially at the beginning. For instance, TwinsMX relies completely on self-registration of volunteers that are reached by our invitations through social media or events, since there is no database available that allows us to identify and contact potential participants, which limits the scope of the project. Besides, it is necessary that all the siblings of a multiple birth complete the surveys; but in most cases, only one of the twins is interested or motivated to finish the questionnaires, which leads to incomplete data. Another limitation is that in Spanish there is a word specifically used for fraternal twins "cuate" (/'kwate/), thus often they do not identify themselves as twins, making them think that they are excluded from the registry. Stronger and more specific media campaigns are currently trying to address this issue.

LupusRGMX mainly works on a voluntary self-registration basis of people reached by our communication campaigns, by far, the main obstacle we have faced has been reaching Mexican individuals with SLE with the interest and disposition to start and complete the surveys: this is reflected on the fact that from the 1761 started registries, only 1271 have completed the clinical questionnaire. Different strategies, such as spacing out survey's invitations, and motivation for participants through dynamics, such as giveaways, have been undertaken in order to increase survey completion. In addition, since the beginning, LupusRGMX, has tried to approach rheumatologists through the Mexican College of Rheumatology, in order to establish collaborations in which the rheumatologist gives a formal clinical evaluation at the beginning of the registry and help their patients through the initial clinical manifestations' questionnaires, improving the reliability of our data. To date, only 147 participants have been registered through this option. With the knowledge that self-reported data can be threatened by self-reporting bias and thus considered as unreliable ⁷³, strategies are being undertaken to assess them; we are currently working on a comparison of the outcomes from self-reported instruments with those provided by patients' medical practitioners to evaluate reliability.

Similarly, as MEX-PD patients must be registered through a Neurologist with expertise to perform a clinical evaluation, reaching people with access to this level of medical care has been challenging. The shortage of Neurologists with valid certification in Mexico ⁷⁴ along with their substantial workloads, driven by the necessity to attend to a large number of patients, limits the scope of the registry. Nonetheless, 774 registries have been recorded so far. Furthermore, as aforementioned, Neurologists in Mexico usually have a heavy workload, making the survey's completion a daunting task. To ease this task, a team of trained assistants help patients complete particular surveys (i.e. environmental exposure), moreover, we are currently working on transferring suitable instruments to be self-completed by participants.

Likewise, a shared challenge between the registries is the need to acquire data from more diverse individuals within Mexico. Reviewing the current progress of the cohorts, it became evident that the majority of registries are representative of the central states of México and from specific regions where we have collaborating associations. For such a reason, we are working on specifically targeting the underrepresented regions of the country, taking advantage of our online tools and the use of social media and the establishment of new collaborations. Collection of biological samples through buccal swabs for DNA obtention is being performed in multiple sites for TwinsMX and MEX-PD, which will allow representation of diverse genetic backgrounds. However, Magnetic Resonance Images acquisition, performed in suitable TwinsMX participants, and blood samples for LupusRGMX, demand on-site presence of participants and are only carried out in Queretaro, limiting the participation of people from northern or southern states in the country. The complexity of this technique and its required infrastructure prevents its mobility to other Mexican states.

Finally, it is relevant to mention that due to that National registries are not common in the Mexican population, constant invitation in traditional and social media is required to continuously boost participation. As of 2020, 72.0% aged six or older Mexico residents are internet users ⁷⁵, therefore the recruitment through social media has shown to be a very effective tool with similar models successfully implemented in other registries ^{76,77}. To date, our registries have implemented an integrative approach through social media, turning them into reliable platforms for the exposition and discussion of topics associated with the interest of the registry's community.

Sharing is caring: community building

As a consortium, we strongly believe that the participants in the three registries are not subjects of study, but active citizens with a major role in biomedical research. As such, it is imperative to observe informed consents, maintain transparent procedures, disclose progress reports, and open communication channels where participants can provide feedback.

As twins, Lupus and Parkinson communities in Mexico were already active, one of the first steps in building the three registries was approaching community leaders, civil organizations, and foundations, which have been a key component in reaching participants and gaining credibility in their communities. TwinsMX, the first of this consortium, received support from the Multiple Birth Association (Asociación de Nacimientos Múltiples, A.C.), but now it holds a significant community by its own, with an important presence in social media with over 3.2K followers in facebook (https://www.facebook.com/TwinsMXofficial) and 748 on instagram, (https://www.instagram.com/twinsmxofficial). TwinsMX's То date, team works constantly the generation of informative in content (https://twinsmxofficial.unam.mx/blog/) and their participation in community activities.

Furthermore, LupusRGMX receives direct support and active participation of representatives of the biggest communities of people with Lupus in the country:

LUPUS MX (https://www.facebook.com/LUPUSMXOficial), Fundación Proayuda Lupus Morelos A.C. (https://www.facebook.com/LUPUSMORELOS), the Centro de Estudios Transdisciplinarios Athié-Calleja por los Derechos de las Personas con Lupus A.C. (https://www.facebook.com/Cetlu), and Despertar de la Mariposa A.C. (https://www.facebook.com/DespertarLupus); who have reviewed the surveys, and expressed their opinions and needs. We have also reached rheumatologists and the Colegio Mexicano de Reumatología, in order to establish collaborations that would help to provide a more integrated evaluation of SLE in our population. The formation of this community has helped us identify necessities and areas of opportunity for clinicians and researchers in order to generate knowledge with future applications and impact on the life of people with lupus. Through the contact of experts on some topics of interest such as pediatric SLE, grief associated with a chronic disease diagnosis, and reproductive health we have established monthly open talks through Facebook Live sessions (https://www.facebook.com/lupusrgmx). Beside these talks, the team of LupusRGMX has been working on providing another sources of reliable information (https://lupusrgmx.liigh.unam.mx/comunicacion.html) and actively participate in activities for lupus acknowledgment in México.

Similarly, MEX-PD has seeked support from the Red Mexicana de Asociaciones de (https://www.facebook.com/RedMXdeAsociacionesdeParkinson), Parkinson and different communities of people with Parkinson's and their close ones, including Parkinson Laredo (https://www.facebook.com/groups/768321520680203) and Asociación Parkinson IAP Mexiquense de (https://www.facebook.com/parkinsonmexiquense).

Perspectives

As a general perspective, TwinsMX, LupusRGMX and MEX-PD will allow us to characterize the genetic and environmental contribution over different traits and diseases with data directly collected in the Mexican population, which is heavily underrepresented in epidemiological and genetic studies. This characterization will provide us medically relevant information that in the future can be useful for better and more accurate diagnosis, treatments, and therapies.

In particular, for TwinsMX we expect to start to collect DNA through saliva samples, not only in twin individuals but also to their direct relatives (i.e. parents and not-twins siblings) in order to build a biobank with valuable data about genetic variants that make Mexicans more prone to develop relevant medical conditions. Also, in the future it is expected to acquire data with electroencephalography (EEG) and to be able to establish an association with cognitive performance. Then, taking together the EEG data, the data from the TwinsMX online registry and the MRI images, we will be able to establish associations between different traits and structural and functional brain properties.

Meanwhile, LupusRGMX has started applying behavioral evaluation of decision making, focused on the choice between social and material incentives and the

temporary discount rate of such incentives. We are currently evaluating if regular glucocorticoid consumption is associated with delayed reaction times in decision-making. Additionally, magnetic resonance images and cognitive function evaluations will be acquired from ninety participants to explore the underlying functional and structural brain biomarkers. Furthermore, as a result of community feedback, LupusRGMX will expand surveys to collect data about reproductive health, allergies, and soon, we will be able to analyze and integrate information recovered from the registry with biomarkers and clinical data.

Finally, MEX-PD is currently performing a control participants recruitment campaign, for which we are working in finding collaborators in as many sites as possible and opening self-completed surveys. Also, as aforementioned, in a short time, we will begin data acquisition for structural and functional MRI, cognition and mental health.

CONCLUSION

Patient registries are fundamental tools in public health research, providing comprehensive population-based data on diseases' etiology and progression. The establishment of registries in Mexico, particularly those initiated by the Universidad Nacional Autónoma de México through the MexOMICS Consortium, has enriched the research landscape with epidemiological and genetic information. These registries enable researchers to explore the complex interplay between genetic factors and environmental influences in traits in the general population by studying twin participants, but also those in complex diseases like systemic lupus erythematosus, and Parkinson's disease. However, limitations, such as inconsistent data entry and patient participation, together with potential biases due to voluntary participation must be addressed to ensure that the creation of these databases can serve as robust foundations for subsequent studies and investigations. The MexOMICS Consortium's registries represent a valuable resource that will help to approach questions associated with health and disease in Mexican people. Future directions involve refinement and expansion, optimizing experimental design, data collection methodologies, and fostering interdisciplinary collaboration.

ACKNOWLEDGMENTS

This work received support from Luis Aguilar, Alejandro León, and Jair García of the Laboratorio Nacional de Visualización Científica Avanzada. We also thank Cesar Arturo Dominguez Frausto, Erick H. Pasaye Alcaraz, Leopoldo González Santos, Carina Uribe Díaz, and Alejandra Castillo Carbajal for their technical support. We thank Mauricio Guzman for designing all logos.

Authors would like to express their special acknowledgment to Fundación Proayuda Lupus Morelos A.C., Lupus MX, El despertar de la Mariposa A.C., Centro de Estudios Transdisciplinarios Athié-Calleja por los Derechos de las Personas con Lupus A.C. (Cetlu), Lupus Tuxtla, Lupus en Yucatán, Asociación de Lupus y AIJ Caminando Juntos A.C., Aprendiendo a Vivir con Lupus y Fibromialgia A.C. and Asociación de Nacimientos Múltiples, A.C. for their invaluable support.

FUNDING STATEMENT

This project was supported by CONACYT-FORDECYT-PRONACES grants no. [11311] and [6390]. AMR was supported by Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica–Universidad Nacional Autónoma de México (PAPIIT-UNAM) grants no. IA203021 and IN218023. SA was supported by Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica–Universidad Nacional Autónoma de México (PAPIIT-UNAM) grants no. IN212219.

ALHL is a doctoral student from Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM) and she receives fellowship 790972 from Consejo Nacional de Humanidades, Ciencias y Tecnologías CONAHCYT, México.

DRG is a doctoral student from Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México (UNAM) and he receives fellowship 1003248 from Consejo Nacional de Humanidades, Ciencias y Tecnologías CONAHCYT, México.

MEX-PD is supported by the American Parkinson's Disease Association through a Diversity in Parkinson's Disease Research Grant (APDA/D07) and though a subaward of the Latin American Research consortium on the GEnetics of Parkinson's Disease (LARGE-PD) funded by The Michael J. Fox Foundation. MEX-PD is also supported by the American Parkinson's Disease Association through a Diversity in Parkinson's Disease Research Grant (APDA/D07).

LupusRGMX was supported by Lupus Research Alliance, 2023 GLOBAL TEAM SCIENCE AWARD Planning Grant to AMR.

MER thanks fellowship support from the Rebecca L Cooper Medical Research Foundation (F20231230).

PRP is supported by the GP2 Trainee Network, which is part of the Global Parkinson's Genetics Program and funded by the Aligning Science Across Parkinson's (ASAP) initiative.

ALF is a doctoral student of the Programa de Doctorado en Psicología de la Universidad Nacional Autónoma de México and she is a scholarship holder who received a grant scholarship (1222481) from CONAHCYT for her Psychology PhD studies.

CONFLICT OF INTEREST

The authors declare they do not have any competing nor conflict of interest in connection with this article.

DATA AVAILABILITY

All data is available upon request to authors, expression of interest can be done through this platform (https://redcap.link/gr4lspyl).

REFERENCES

- 1. Gliklich RE, Drever NA, Leavy MB. Patient Registries. Agency for Healthcare Research and Quality (US), 2014.
- 2. Kodra Y, Posada de la Paz M, Coi A, et al. Data Quality in Rare Diseases Registries. In: Posada de la Paz M, Taruscio D, Groft SC (eds) Rare Diseases Epidemiology: Update and Overview. Cham: Springer International Publishing, 2017, pp. 149-164.
- 3. Thompson R, Johnston L, Taruscio D, et al. RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J Gen Intern Med 2014; 29 Suppl 3: S780-7.
- 4. Irgens LM. The origin of registry-based medical research and care. Acta Neurol Scand Suppl 2012; 4–6.
- Merabishvili V. Review Cancer incidence in Five Continents Vol. XI / Ed. by F. 5. Bray, M. Colombet, L. Mery, M. Piñeros, A. Znaor, R. Zanetti and J. Ferlay. IARC Sci. publ. № 166, Lyon, France, 1545 p. Problems in oncology 2021; 67: 855.
- 6. Dawson LP, Biswas S, Lefkovits J, et al. Characteristics and Quality of National Cardiac Registries: A Systematic Review. Circ Cardiovasc Qual Outcomes 2021: 14: e007963.
- Weintraub WS. Role of Big Data in Cardiovascular Research. J Am Heart Assoc 7. 2019: 8: e012791.
- 8. Piñeros M, Abriata MG, Mery L, et al. Cancer registration for cancer control in Latin America: a status and progress report. Rev Panam Salud Publica 2017; 41: e2.
- 9. Hur Y-M, Bogl LH, Ordoñana JR, et al. Twin Family Registries Worldwide: An Important Resource for Scientific Research. Twin Res Hum Genet 2019; 22: 427-437.
- 10. Bakken IJ, Ariansen AMS, Knudsen GP, et al. The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: Research potential of two nationwide health-care registries. Scand J Public Health 2020; 48: 49-55.
- 11. Cancer registries. Int J Oral Surg 1975; 4: 215.
- 12. Morsy A, Lim TO, Varatharajan S, et al. National registries in developing countries: Understanding construction challenges and implementation steps. In: 2010 5th Cairo International Biomedical Engineering Conference. 2010, pp. 75-78.
- 13. Gutiérrez JP, García-Saisó S, Dolci GF, et al. Effective access to health care in Mexico. BMC Health Serv Res 2014; 14: 186.
- 14. Instituto Nacional de Estadística y Geografía (INEGI). Derechohabiencia, https://www.inegi.org.mx/temas/derechohabiencia/ (accessed 8 March 2022).
- 15. ¿De qué mueren los mexicanos?, https://www.insp.mx/avisos/5111-dia-muertosmexicanos.html (accessed 27 January 2023).
- 16. Lara-Vaca S, Cordero-Cabra A, Martínez-Flores E, et al. Registro Mexicano de Fibrilación Auricular (ReMeFa). Gac Med Mex 2014; 150: 48-59.
- 17. Cervantes-Salazar J, Calderón-Colmenero J, Ramírez-Marroquín S, et al. El Registro Mexicano de Cirugía Cardiaca Pediátrica. Primer informe. Evid Med Invest Salud 2014; 7: 56–62.

- 18. Arturo OT, Lilia CM, Sergio FS, et al. Programa Nacional de Registro de Insuficiencia Cardiaca, https://www.imbiomed.com.mx/articulo.php?id=25925 (accessed 27 January 2023).
- 19. Vega-Morales D, Esquivel-Valerio JA, Vázquez-Fuentes BR, et al. Comorbidity burden in terms of disability in patients with osteoarthritis in Mexico. The IMPACTAR registry. Reumatol Clin 2021; 17: 440-446.
- 20. Faradii RN, Valenzuela-Lara M, Vidrio-Velázquez M, et al. RENACED-DT1: A National Type 1 Diabetes Registry Initiative in Mexico. Salud Publica Mex 2020: 62: 232-234.
- 21. González-Hermosillo JA, Márguez MF, Ocampo-Peña S, et al. [Design of an atrial fibrillation and embolic risk registry in Mexico: CARMEN-AF]. Arch Cardiol Mex 2017; 87: 5–12.
- 22. DOF Diario Oficial de la Federación, http://dof.gob.mx/nota_detalle.php?codigo=5280847&fecha=30/11/2012 (accessed 8 March 2022).
- 23. Morales-Rocha VM. Technical reference framework for the interoperability of electronic medical record: Conceptual model. Revista Mexicana de Ingenieria Biomedica. Epub ahead of print 2020. DOI: 10.17488/rmib.41.1.8.
- 24. Gordon H, Trier Moller F, Andersen V, et al. Heritability in inflammatory bowel disease: from the first twin study to genome-wide association studies. Inflamm Bowel Dis 2015; 21: 1428-1434.
- 25. Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc 2012; 19: 212-218.
- 26. arcOGEN Consortium, arcOGEN Collaborators, Zeggini E, et al. Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet 2012; 380: 815-823.
- 27. Leon-Apodaca AV, Chiu-Han E, Ortega-Mora I, et al. TwinsMX: Uncovering the Basis of Health and Disease in the Mexican Population. Twin Res Hum Genet 2019; 22: 611-616.
- 28. Hernández-Ledesma AL, Martínez D, Fajardo-Brigido E, et al. Lupus RGMX: Social and clinical characteristics and their contribution to quality of life in a Mexican cohort with SLE. *bioRxiv*. Epub ahead of print 24 February 2023. DOI: 10.1101/2023.02.23.23286331.
- 29. Lázaro-Figueroa A, Reyes-Pérez P, Morelos-Figaredo E, et al. MEX-PD: A National Network for the Epidemiological & Genetic Research of Parkinson's Disease. medRxiv 2023; 2023.08.28.23294700.
- 30. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.
- 31. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-381.
- 32. Gliklich RE, Leavy MB, Cosgrove L, et al. Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practice. Ann Intern Med 2020: 172: 803-809.
- 33. Hopper JL, Foley DL, White PA, et al. Australian Twin Registry: 30 years of progress. Twin Res Hum Genet 2013; 16: 34-42.
- 34. Moayyeri A, Hammond CJ, Hart DJ, et al. The UK Adult Twin Registry (TwinsUK) Resource). Twin Res Hum Genet 2013; 16: 144–149.

- 35. Australian Parkinson's Genetics Study. QIMR Berghofer. https://www.gimrberghofer.edu.au/apgs/ (2022, accessed 18 April 2022).
- 36. Large-PD Large-PD, https://large-pd.org/ (accessed 18 April 2022).
- 37. NSE, https://www.amai.org/NSE/index.php?gueVeo=NSE2020 (accessed 7 July 2023).
- 38. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
- 39. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019; 78: 1151–1159.
- 40. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
- 41. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 1998; 50: 318 and 16 pages following.
- 42. Martín-Carbonell M, Riguelme-Marín A, Ortigosa-Quiles JM, et al. Utilidad del Inventario de Depresión Rasgo-Estado (IDERE) para el diagnóstico clínico. Un estudio con muestras de cuatro países iberoamericanos. Anales de Psicología 2012; 28: 763-771.
- 43. Spielberger CD. Manual for the state-trait anxiety inventory (self-evaluation guestionnaire). (No Title), https://cir.nii.ac.jp/crid/1370285712575158016 (1970, accessed 12 July 2023).
- DE 44. Garcia Β. 19 ESCALAS **EVALUACION** PSICOLOGICA, https://www.academia.edu/31038102/19 ESCALAS DE EVALUACION PSIC OLOGICA (2017, accessed 28 August 2023).
- 45. Palomar Lever J, Gómez Valdez NE. Desarrollo de una escala de medición de la resiliencia con mexicanos (RESI-M). Interdiscip Archaeol 2010; 27: 7-22.
- 46. Oddy M. The Use of Psychological Testing for Treatment Planning and Outcomes Assessment (2nd edn) Edited by Mark E. Maruish London: Lawrence Erlbaum. 1999. 1507 pp. £200.00 (hb). ISBN 0 80582761 7. British Journal of Psychiatry 2001; 178: 93–94.
- 47. Tobin DL, Holroyd KA, Reynolds RV, et al. The hierarchical factor structure of the coping strategies inventory. Cognit Ther Res 1989; 13: 343-361.
- 48. Leentjens AFG, Dujardin K, Pontone GM, et al. The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 2014; 29: 1035-1043.
- 49. Escala Breve de Inteligencia, https://tienda.manualmoderno.com/escala-brevede-inteligencia-89-100.html (accessed 7 September 2023).
- 50. Sánchez-Moncada I, Concha L, Merchant H. The timing network is engaged in the practice of internally driven tapping independently of the learning transfer from perceptual to motor timing. *bioRxiv* 2020; 2020.12.17.423301.
- 51. Lizcano-Cortés F, Gómez-Varela I, Mares C, et al. Speech-to-Speech Synchronization protocol to classify human participants as high or low auditorymotor synchronizers. STAR Protoc 2022; 3: 101248.
- 52. Ruiz-Contreras AE, Soria-Rodríguez G, Almeida-Rosas GA, et al. Low diversity and low frequency of participation in leisure activities compromise working memory efficiency in young adults. Acta Psychol 2012; 139: 91-96.
- 53. Hampshire A, Highfield RR, Parkin BL, et al. Fractionating human intelligence. Neuron 2012; 76: 1225-1237.

- 54. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005: 53: 695-699.
- 55. Parker G, Tupling H, Brown LB. A parental bonding instrument. Br J Med Psychol 1979; 52: 1–10.
- 56. Bernstein DP, Fink L, Handelsman L, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry 1994; 151: 1132-1136.
- 57. Rao SC, Pattipati S, Salim A, et al. Promoting Gender Inclusivity: A Questionnaire for Women's Health Factors in Parkinson's Disease. Movement disorders: official journal of the Movement Disorder Society 2022; 37: 1112–1113.
- 58. Jiménez-Genchi A, Monteverde-Maldonado E, Nenclares-Portocarrero A, et al. Confiabilidad y análisis factorial de la versión en español del índice de calidad de sueño de Pittsburgh en pacientes psiguiátricos. Gac Med Mex 2008; 144: 491-496.
- 59. WHOQOL measuring Quality of life, https://www.who.int/tools/whogol (accessed 7 July 2023).
- 60. Zúniga MA, Carrillo-Jiménez GT, Fos PJ, et al. [Evaluation of health status using Survey SF-36: preliminary results in Mexico]. Salud Publica Mex 1999; 41: 110-118.
- 61. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 972–979.
- 62. Boyle GJ, Matthews G, Saklofske DH. Personality theories and models: An overview. The SAGE handbook of personality theory and assessment, Vol 1: Personality theories and models 2008; 1: 1–29.
- 63. Muris P, Meesters C, de Kanter E, et al. Behavioural inhibition and behavioural activation system scales for children: Relationships with Eysenck's personality traits and psychopathological symptoms. Pers Individ Dif 2005; 38: 831-841.
- 64. Fadanelli B, del Pilar M. Actitud hacia la ingesta y peso corporal. Acta médica Grupo Angeles 2014; 12: 181–188.
- 65. Global physical activity questionnaire (GPAQ), https://www.who.int/publications/m/item/global-physical-activity-guestionnaire (accessed 28 August 2023).
- 66. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
- 67. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption -- II. Addiction 1993; 88: 791-804.
- 68. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcoholdependent clinical sample. Drug Alcohol Rev 2003; 22: 309-315.
- 69. Nucci M, Mapelli D, Mondini S. Cognitive Reserve Index guestionnaire (CRIg): a new instrument for measuring cognitive reserve. Aging Clin Exp Res 2012; 24: 218-226.
- 70. Ordoñana JR, Bartels M, Boomsma DI, et al. Biological pathways and genetic mechanisms involved in social functioning. Qual Life Res 2013; 22: 1189-1200.
- 71. Oldfield RC. The assessment and analysis of handedness: the Edinburgh

inventory. Neuropsychologia 1971; 9: 97-113.

- 72. Vailati-Riboni M, Palombo V, Loor JJ. What Are Omics Sciences? In: Ametaj BN (ed) Periparturient Diseases of Dairy Cows: A Systems Biology Approach. Cham: Springer International Publishing, 2017, pp. 1–7.
- 73. Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc 2016; 9: 211-217.
- 74. Heinze G, Canchola VHO, Miranda GB, et al. Los médicos especialistas en México. Gac Med Mex 2018; 154: 342-351.
- 75. Instituto Nacional de Estadística y Geografía (INEGI). En hogares. https://www.inegi.org.mx/temas/ticshogares/ (accessed 8 March 2022).
- 76. Zwan MD, van der Flier WM, Cleutjens S, et al. Dutch Brain Research Registry for study participant recruitment: Design and first results. Alzheimers Dement 2021; 7: e12132.
- 77. Obrutu O, Maughan J, Tjoe B, et al. Smidt Heart Institute Takotsubo Registry -Study design and baseline characteristics. American Heart Journal Plus: Cardiology Research and Practice 2022; 13: 100086.




Figure 2. Geographic and age distribution of volunteers for TwinsMX (n=2915), LupusRGMX (n=1761) and E=MEX-PD (n=774). Age distribution for TwinsMX (upper-left), LupusRGMX (middle-left) and MEX-PD (bottom-left). Geographic distribution for TwinsMX (upper-right), LupusRGMX (middle-right) and MEX-PD (bottom-right).



Figure 1. Logos designed for A) MexOMICS, B) TwinsMX, C) LupusRGMX and D) MEX-PD.